MAG Optics

Executive Summary

Keratoconus is a progressive, bilateral eye disease characterized by corneal thinning and cone-like steepening, leading to distorted vision, halos, glares, and functional blindness in advanced stages. Current treatments include specialty contact lenses, corneal cross-linking, and transplants, but many patients struggle with comfort, fit, and access. There is a significant unmet need for innovative, comfortable, and accessible solutions that improve visual outcomes and quality of life. MAG Optics, based in Rochester, NY, since 2003, is a private medical device company focused on keratoconus management. While specific product details are limited, the company likely develops advanced optical devices such as scleral or hybrid contact lenses designed to correct irregular astigmatism and provide stable vision. With over two decades in the field, MAG Optics may possess proprietary fitting technologies or materials that enhance comfort and visual acuity. The company operates in the ophthalmology space, targeting a growing patient population as awareness and diagnosis rates increase.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of next-generation scleral lens70% success
• Q2 2026Completion of pivotal clinical trial for keratoconus device60% success
• Q4 2026Strategic partnership with major ophthalmology clinic chain80% success